Dihydroartemisinin not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dihydroartemisinin 40mg, taken orally twice a day, for a treatment period of 24 weeks.”In the company’s words, NCT07557927 on ClinicalTrials.gov
- Tested for
- Discoid Lupus Erythematosus
- Main trialPhase 2
- “This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid lupus erythematosus (DLE).”In the company’s words, NCT07557927 on ClinicalTrials.gov
Other drugs for Discoid Lupus Erythematosus
- EnpatoranEMD Serono Research & Development Institute, Inc. · Phase 3
- LitifilimabBiogen · Phase 3
- AfimetoranBeeline Medicines Corporation · Bristol Myers Squibb · Phase 2/3
- AnifrolumabAstraZeneca · Phase 3
- DeucravacitinibBristol Myers Squibb · Phase 2
- ImeroprubartImmunovant Sciences GmbH · Phase 2
Coming up1
- 30 Sep 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Sep 2028 | A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026